Potential role of some nutraceuticals in the regression of Alzheimer's disease in an experimental animal model

Turkish Journal of Medical Sciences

Volumn 41, Issue 3, 2011, Pages 455-466

  Ahmed, Hanna Hamdy ^a   Shousha, Wafaa Ghoneim ^b   Hussien, Rehab Mahmoud ^b   Farrag, Abdel Razik Hussein ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b Helwan University   (Egypt)

Author keywords

Aluminum; Alzheimer's disease; CoQ10; Lecithin; Rats; Vitamin B

Indexed keywords

ACETYLCHOLINESTERASE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CYANOCOBALAMIN; FOLIC ACID; GLUTATHIONE; HOMOCYSTEINE; NITRIC OXIDE; PHOSPHATIDYLCHOLINE; UBIDECARENONE; VITAMIN B COMPLEX;

ACETYLCHOLINE BRAIN LEVEL; ALZHEIMER DISEASE; AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; FOLIC ACID BLOOD LEVEL; GLUTATHIONE METABOLISM; HISTOPATHOLOGY; LIPID PEROXIDATION; MALE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; POTASSIUM TRANSPORT; RAT; SODIUM TRANSPORT; VITAMIN BLOOD LEVEL;

EID: 79955514890     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-0907-136     Document Type: Article

References (72)

1. Farina M, Lara FS, Brandao R, Jacques R, Rocha JBT. Effects of aluminum sulfate on erythropoiesis in rats. Toxicol Lett 2002; 132: 131-39.
2. Kim MS, Lenore S, Clesceri LS. Aluminum exposure: a study of an effect on cellular growth rate. Sci Total Environ 2001; 278: 127-35.
3. Levesque L, Mizzen CA, McLachlan DR, Fraser PE. Ligand specific effects on aluminium incorporation and toxicity in neurons and astrocytes. Brain Res 2000; 877: 191-202.
4. Nayak P. Aluminum: Impacts and Disease. Environ Res Sect 2002; 89: 101-15.
5. Flaten TP. Aluminum as a risk factor in Alzheimer's disease, with emphasis on drinking water. Brain Research Bulletin 2001; 55: 187-96.
6. Mattson MP. Pathways towards and away from Alzheimers disease. Nature 2004; 430: 631-39.
7. Exely C. The aluminium-amyloid cascade hypothesis and Alzheimer's disease. Subcell Biochem 2005; 38: 225-34.
8. Campbell A. Aluminum increases levels of beta-amyloid and ubiquitin in neuroblastoma but not in glioma cells. Proceedings of the Society for Experimental Biology and Medicine 2000; 223: 397-402.
9. Bus AI, Huang X, Fairlie DP. The possible origin of free radicals from amyloid beta peptides in Alzheimers disease. Neurobiol Aging 1998; 20: 335-37.
10. Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacology and Therapeutics 2007; 113: 154-64.
11. Babich H, Liebling EJ, Burger RF, Zuckerbraun HL, Schuck AG. Choice of DMEM, formulated with or without pyruvate, plays an important role in assessing the in vitro cytotoxicity of oxidants and prooxidant nutraceuticals. In Vitro Cell Dev Biol Anim 2009; 45: 226-33.
12. Cornelli U. Antioxidant use in nutraceuticals. Clin Dermatol 2009; 27: 175-94.
13. Morganti P. The photoprotective activity of nutraceuticals. Clin Dermatol 2009; 27: 166-74.
14. 10 in chronic heart failure, angina, and hypertension. Pharmacotherapy 2001; 21: 797-806.
15. Meins W, Muller-Thomsen T, Meier-Baumgartner HP. Subnormal serum vitamin B12 and behavioural and psychological symptoms in Alzheimer's disease. Int J Geriatr Psychiatry 2007; 15: 415-18.
16. Sruerenburg HJ, Mueller-Thomsen T, Methner A. Vitamin B12 plasma concentrations in Alzheimer disease. Neuro Endocrinol Lett 2004; 25: 176-77.
17. Rodríguez-Martín JL, Qizilbash N, López-Arrieta JM. Thiamine for Alzheimer's disease. Cochrane Database Syst Rev 2001; 2: CD001498.
18. Chung SY, Moriyama T, Uezu E, Uezu K, Hirata R, Yohena N. Administration of phosphatidylcholine increases brain acetylcholine concentration and improves memory in mice with dementia. J Nutr 1995; 125: 1484-89.
19. Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev 2003; 3: CD0011015.
20. Dave KR, Syal AR, Katyare SS. Effect of long-term aluminum feeding on kinetic attributes of tissue cholinesterases. Brain Res Bull 2002; 58: 225-33.
21. 10 does not prevent oral dyskinesias induced by long-term haloperiodol treatment of rats. Pharmacology Biochemistry and Behavior 1999; 64: 637-42.
22. Hung NK, Wan FJ, Tseng CJ, Tung CS. Nicotinamide attenuates methamphetamine-induced striatal dopamine depletion in rats. Neuroreport 1997; 8: 1883-85.
23. Suzuki S, Yamatoya H, Sakai M, Kataoka A, Furushiro M, Kudo S. Oral administration of soybean lecithin transphosphatidylated phosphatidylserine improves memory impairement in aged rats. Nutration Org 2001; 131: 2951-56.
24. Den Blawen DH, Poppe WA, Trischier W. 1983. Cholinesterase (EC 3.1.1.8) with butyryl thiocholine-iodide as substrate: reference depending on age and sex with special reference to hormonal effect and pregnancy. J Clin Chem Biochem 1983; 21: 381-86.
25. Tsakiris S, Schulpis KH, Marinou K, Behrakis P. Protective effect of L- cysteine and gluthathione on the modulated suckling rat brain Na+, K+-ATPase and Mg2+-ATPase activities induced by the in vitro galactosaemia. Pharmacological Research 2004; 49: 475-79.
26. Satoh K, Serum lipid peroxide in cerebrovascular disorders determined by a new colormetric method. Clinica Chimica Aclo 1978; 90: 37-48.
27. Ellman GL. Tissue Sulfhydryl groups. Arch. Biochem. Biophys 1959; 74: 214-18.
28. Berkels R, Purol-Schnabel S, Roesen R. Measurment of nitric oxide by reconversion of nitrate/nitrite to NO. J Human Press 2004; 279: 1-8.
29. Higgins T, Wu A. 1983. Differences in vitamin B12 results as measured with boil and no boil kits. Clin Chem 1983; 29: 587-88.
30. Frantzen F, Faaren AL, Alfheim I, Nordhei AK. An enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998; 44: 311-16.
31. Drury RAB, Wallington EA. Preparation and fixation of tissues in carletons hisological technique. 4th ed Oxford: Oxford University Press: 1980.
32. Snedecor GW, Cochran WG. Statistical methods, 7th ed. Iowa State Unive. Pree Iowa USA; 1980.
33. Gulya K, Rakonczay Z, Kasa P. Cholinotoxic Effects of Aluminum in Rat Brain Neurochem 1990; 51: 1020-26.
34. Platt B, Fiddler G, Riedel G, Henderson Z. Aluminium toxicity in the rat brain: histochemical and immunocytochemical evidence. Brain Res Bull 2001; 55: 257-67.
35. Arendt T, Bigl V, Tennstedt A, Arendt A. Correlation between cortical plaque count and neuronal loss in the nucleus basalis in Alzheimers disease. Neurosci Lett 1984; 48: 81-5.
36. Brinton RD. Impact of estrogen therapy on AD: A fork in the road. CNS Drugs 2004; 18: 405-22.
37. Caroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, La Ferla FM et al. Progesterone and estrogen regulate Alzheimers neuropathology in female 3Tg-AD mice. J Neuroscience 2007; 27: 13357-65.
38. Candore J, Balistreri CR, Listi F, Grimaldi MP, Vasto S, Colonna RG et al. Immunogenetics, gender and longevity. Ann Ny Academic Sci 2006; 1089: 516-37.
39. Li L, Cao D, Desmond R, Rahman A, Lah JJ, Levey AI et al. Cognitive Performance and plasma levels of Homocysten, Vit. B12 Folate and lipids in patient with AD. Demant Gerietr Cogn Disord 2008; 26: 384-90.
40. Lynch T, Cherny RA, Bush AI. Oxidative processes in Alzheimers disease: the role of beta-metal interactions. Exp Gerontol 2004; 35: 4454-51.
41. Clarke R, Sherliker P, Hin H, Nexo E, Hvas AM, Schneede J et al. Detection of vitamin B12 deficiency in older people by measuring vitamin B12 or the active fraction of vitamin B12, holotranscobalamin. Clin Chem 2007 53: 963-70.
42. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M et al. Homocysteine, folate and vitaminB-12 in mild cognitive impairment, Alzheimers disease, and vascular dementia. J Clin Nutr 2004; 80: 114-22.
43. McCaddon A, Regland B, Hudson P, Davies G. Functional vitamin B (12) deficiency and Alzheimer disease. Neurology 2002; 58: 1395-99.
44. Kado DM, Karlamangla AS, Huang MH, Troen A, Rowe JW, Selhub J et al Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Medicine 2005; 118: 16-67.
45. Kruman II, Clumsee C, Chan S. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000; 20: 6920-26.
46. Algaidi SA, Christie LA, Jenkinson AM, Whalley L, Riedel G, Platt B. Long-term homocysteine exposure induced alterations in spatial learning, hippocampal signaling and synaptic plasticity. Exp Neurol. 2006; 197: 8-21.
47. Streck EL, Delwing D, Tagliari B, Matte C, Wannmacher CM, Wajner M et al. Brain energy metabolism is compromised by the metabolites accumulating in homocystinuria. Neurochem Int 2003; 43: 597-602.
48. Campbell A, Prasad KM, Bondy SC. Aluminum induced oxidative events in cell lines: gliomas are more responsive than neuroblastoma. Free Radical Biol Med 1999; 26: 1166-71.
49. Yokel RA. The toxicology of aluminum in the brain: a review. Neurotoxicol 2000; 21: 813-28.
50. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Natr 2000; 71: 621S-29S.
51. Zatta P. In vivo and in vitro effects of aluminum on the activity of mouse brain acetylcholinesteras. Research Bulletin 2002; 59: 41-5.
52. Wüllner U, Seyfried J, Groscurth P, Beinroth S, Winter S, Gleichmann M et al. Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function. Brain Res 1999; 826: 53-62.
53. Bondy SC, Liu D, Guo-Ross S. Aluminum treatment induces nitric oxide synthase in the rat brain. Neurochem Int 1998; 33: 51-4.
54. Guo CH, Lin GY, Yeh MS, Wang GS. Aluminum induced suppression of testosterone through nitric oxide production in male mice. J ETAP 2005; 19: 33-40.
55. Anasolla K, Khan M, Singh AK, Singh I. Inflammatory mediator and β-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. J Free Rad Biol 2004; 37: 325-38.
56. Akama KT, Albanese C, Pestell RG, Van Eldik LJ. Amyloid betapeptide stimulates nitric oxide production in astrocytes through an Nfkappa B-dependent mechanism. Proc Natl Acad Sci USA 1998; 95: 5795-800.
57. 10) on superoxide dismutase activity in ET-1 and ET-3 experimental models of cerebral ischemia in the rat. Folia Neuropathol 1999; 37: 247-51.
58. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta 1995; 1271: 195-204.
59. 10) and mitochondria in oxidative stress of parkinson's disease. Biol. Signals Recept 2001; 10: 224-53.
60. Kwong LK, Kamzalov S, Rebrin I, Bayne ACV, Jana CK, Morris P et al. Effects of coenzyme Q (10) administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Radical Biol Med 2002; 33: 627-38.
61. Gomez-Diaz C, Buron MI, Alcain FJ, Gonzalez-Ojeda R, Gonzalez-Reyes JA, Bello RI et al. Effect of dietary coenzyme Q and fatty acids on the antioxidant status of rat tissues. Protoplasma 2003; 221: 11-17.
62. Ostrowski RP. Effect of coenzyme Q (10) on biochemical and morphological changes in experimental ischemia in the rat brain. Brain Res Bull. 2000; 53: 399-407.
63. Baydar T, Nagymajtenyi L, Isimer A, Sahin G. Effect of folic acid supplementation on aluminum accumulation in rats. J Nutr 2005; 21: 406-10.
64. Fuso A, Seminara L, Cavallaro RA, Anselmi F, Scarpa S. SAdenosylmethionine/ homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PSI and BACE and beta-amyloid production. Mol Cell Neurosci 2005; 28: 195-204.
65. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI. Williams, SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006; 354: 2764-72.
66. Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev 2000; 4: CD001015.
67. Schwartz K. 4th Colloquium on Neuromuscular Diseases. Neuromuscul Disord 1991: 1: 299-304.
68. Amenta F, Parnetti L, Gallai V, Wallin A. Treatment of cognitive dysfunction associated with Alzheimers disease with cholinergic precursors: Ineffective treatments or inappropriate approches. Mech Aging Dev. 2001; 122: 2025-40.
69. Lopez OL, Becker JT. Treatment of Alzheimers disease. Rev Neurol 2002; 35: 850-59.
70. Sergeant N, Wattez A, Galvan-Valencia M, Ghestem A, David JP, Lemoine J et al. Association of ATP synthase α-chain with neurofibrillary degeneration in Alzheimer's disease. Neurosci. 2003; 117: 293-303.
71. Hoane MR, Gillbert DR, Holland MA, Pierce JL. Nicotinamide reduces acute cortical neuronal death and edema in the traumatically injured brain. Neurosci Lett 2006; 408: 35-9.
72. Muma NA, Rowell PP. Effects of chronic choline and lecithin on mouse hippocampal dendritic spine density. Exp Aging Res 1988; 14: 137-41.